We hypothesized that modulation of Nrg1 levels and/or secretase activity may constitute a unifying treatment strategy for CMT neuropathies with focal hypermyelination as it could restore normal levels of myelination. This evidence concerns the gene NRG1 and Charcot-Marie-Tooth disease.